Literature DB >> 1441732

Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen.

J W Newland1, T L Hale, S B Formal.   

Abstract

The construction and characterization of EcSf2a-2, an aroD-deleted Escherichia coli-Shigella hybrid vaccine carrying chromosomal and plasmid genes from Shigella flexneri and expressing S. flexneri 2a somatic antigen in association with E. coli K12 core are described. Expression of hybrid lipopolysaccharide and deletion of aroD resulted in the attenuation of phenotypic characteristics associated with pathogenicity. The addition of an aroD deletion results in a requirement for an aromatic precursor of para-aminobenzoic acid (PABA), an essential bacterial metabolite not present in mammalian tissues. The biosynthesis of hybrid somatic antigen prevents expression of a Sereny-positive reaction by invasive bacteria capable of expressing a plaque-positive phenotype. A functional kcpA gene is required for expression of the plaque-positive phenotype. The presence of an aroD deletion does not interfere with expression of an invasive phenotype; however, in bacteria containing a functional kcpA gene, replication and spread by invading bacteria are limited, preventing development of the plaque-positive phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1441732     DOI: 10.1016/0264-410x(92)90512-i

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.

Authors:  A B Hartman; L L Van de Verg; C R Mainhart; B D Tall; S J Smith-Gill
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

5.  Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri.

Authors:  M M Venkatesan; M B Goldberg; D J Rose; E J Grotbeck; V Burland; F R Blattner
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

6.  Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Authors:  T S Coster; C W Hoge; L L VanDeVerg; A B Hartman; E V Oaks; M M Venkatesan; D Cohen; G Robin; A Fontaine-Thompson; P J Sansonetti; T L Hale
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

7.  Bacterial conjugation in the cytoplasm of mouse cells.

Authors:  Yin Mei Lim; Ad J C de Groof; Mrinal K Bhattacharjee; David H Figurski; Eric A Schon
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

8.  Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals.

Authors:  Z Chen; H Wang; C D'Souza; S Sun; L Kostenko; S B G Eckle; B S Meehan; D C Jackson; R A Strugnell; H Cao; N Wang; D P Fairlie; L Liu; D I Godfrey; J Rossjohn; J McCluskey; A J Corbett
Journal:  Mucosal Immunol       Date:  2016-05-04       Impact factor: 7.313

9.  Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.

Authors:  Rezwanul Wahid; Jakub K Simon; Wendy L Picking; Karen L Kotloff; Myron M Levine; Marcelo B Sztein
Journal:  Clin Immunol       Date:  2013-03-26       Impact factor: 3.969

10.  Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.

Authors:  A B Hartman; L L Van De Verg; M M Venkatesan
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.